[Articles] Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial
3 months of aGPi DBS is insufficient to decrease tic severity for patients with Tourette's syndrome. Future research is needed to investigate the efficacy of aGPi DBS for patients over longer periods with optimal stimulation parameters and to identify potential predictors of the therapeutic response. (Source: Lancet Neurology)
Source: Lancet Neurology - June 20, 2017 Category: Neurology Authors: Marie-Laure Welter, Jean-Luc Houeto, St éphane Thobois, Benoit Bataille, Marc Guenot, Yulia Worbe, Andreas Hartmann, Virginie Czernecki, Eric Bardinet, Jerome Yelnik, Sophie Tezenas du Montcel, Yves Agid, Marie Vidailhet, Philippe Cornu, Audrey Tanguy, S Tags: Articles Source Type: research
[Comment] Deep brain stimulation in Tourette's syndrome: new insights
Hallmarked by multiple motor and phonic tics, Tourette's syndrome is a remarkable neuropsychiatric disease. The syndrome often involves diverse psychiatric comorbidities and coexisting psychopathologies1 and seemingly relates to fronto-striato-thalamo-cortical dysfunction.2 Although deep brain stimulation (DBS) is well established as an effective therapy for other hyperkinetic movement disorders, it has so far been tested in only a few patients with severe Tourette's syndrome. Thus, most of the studies that have been reported have been small and uncontrolled trials, applying DBS to different structures within the fronto-st...
Source: Lancet Neurology - June 20, 2017 Category: Neurology Authors: David J Pedrosa, Lars Timmermann Tags: Comment Source Type: research
[Articles] Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
The multidomain progression measure in TRACK-HD was associated with a functional variant that was genome-wide significant in our meta-analysis. The association in only 216 participants implies that the progression measure is a sensitive reflection of disease burden, that the effect size at this locus is large, or both. Knockout of Msh3 reduces somatic expansion in Huntington's disease mouse models, suggesting this mechanism as an area for future therapeutic investigation. (Source: Lancet Neurology)
Source: Lancet Neurology - June 19, 2017 Category: Neurology Authors: Davina J Hensman Moss, Antonio F Pardi ñas, Douglas Langbehn, Kitty Lo, Blair R Leavitt, Raymund Roos, Alexandra Durr, Simon Mead, TRACK-HD investigators, REGISTRY investigators, Peter Holmans, Lesley Jones, Sarah J Tabrizi Tags: Articles Source Type: research
[Articles] Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial
Dual lead thalamic DBS might be a safe and effective option for improving severe, refractory multiple sclerosis tremor. Larger studies are necessary to show whether this technique is widely applicable, safe in the long-term, and effective in treating multiple sclerosis tremor or other severe tremor disorders. (Source: Lancet Neurology)
Source: Lancet Neurology - June 19, 2017 Category: Neurology Authors: Seth F Oliveria, Ramon L Rodriguez, Dawn Bowers, Daniel Kantor, Justin D Hilliard, Erin H Monari, Bonnie M Scott, Michael S Okun, Kelly D Foote Tags: Articles Source Type: research
[Comment] Identifying modifiers of Huntington's disease progression
Researchers are now harvesting the first fruits of their labour from nearly two decades of tremendous efforts to track progression of Huntington's disease in the manifest and premanifest phases. Large observational studies such as PREDICT-HD,1 COHORT,2 REGISTRY,3 and TRACK-HD4 have aimed to find objective measures of disease progression and learn about the course of the disease. The work to measure disease progression is ongoing. The global, observational study ENROLL-HD5 is currently recruiting and is intended to become the largest study of Huntington's disease. (Source: Lancet Neurology)
Source: Lancet Neurology - June 19, 2017 Category: Neurology Authors: Carsten Saft Tags: Comment Source Type: research
[Comment] Multiple sclerosis tremor: are technical advances enough?
Tremor is the most common disorder in patients with multiple sclerosis and greatly contributes to the disability of these patients. This tremor rarely presents with the high-frequency action component seen in primary tremor disorders; rather, it is the combination of several features, particularly cerebellar ones. Therefore, drugs are rarely effective, whereas surgery can provide variable results depending on the severity of the underlying ataxia. In The Lancet Neurology, Seth Oliveria and colleagues1 report the findings from their single centre, single-blind, prospective, randomised pilot trial of dual-lead thalamic deep ...
Source: Lancet Neurology - June 19, 2017 Category: Neurology Authors: Derrick Soh, Alfonso Fasano Tags: Comment Source Type: research
[Articles] Prediction of cognition in Parkinson's disease with a clinical –genetic score: a longitudinal analysis of nine cohorts
Our predictive algorithm provides a potential test for future cognitive health or impairment in patients with Parkinson's disease. This model could improve trials of cognitive interventions and inform on prognosis. (Source: Lancet Neurology)
Source: Lancet Neurology - June 16, 2017 Category: Neurology Authors: Ganqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, Brendon Boot, Zhixiang Liao, Kara Page, Daly Franco, Kyle Burke, Iris E Jansen, Ana Trisini-Lipsanopoulos, Sophie Winder-Rhodes, Caroline M Tanner, Anthony E Lang, Shirley Eberly, Alexis Elbaz, Alex Tags: Articles Source Type: research
[Comment] A new tool to identify patients with Parkinson's disease at increased risk of dementia
Many patients with Parkinson's disease develop dementia; some patients develop dementia within the first 5 years after diagnosis of Parkinson's disease, whereas others remain free of dementia for more than 10 –15 years after diagnosis.1 Identification of individuals at the highest risk of early dementia is important for the development of targeted intervention strategies for the primary prevention of dementia and for enabling future planning for patients, carers, and delivery of true personalised medic ine. (Source: Lancet Neurology)
Source: Lancet Neurology - June 16, 2017 Category: Neurology Authors: Dag Aarsland, Byron Creese, K Ray Chaudhuri Tags: Comment Source Type: research
[Personal View] Gadolinium deposition in the brain: summary of evidence and recommendations
Emerging evidence has linked MRI signal changes in deep nuclei of the brain with repeated administration of gadolinium-based contrast agents. Gadolinium deposits have been confirmed in brain tissue, most notably in the dentate nuclei and globus pallidus. Although some linear contrast agents appear to cause greater MRI signal changes than some macrocyclic agents, deposition of gadolinium has also been observed with macrocyclic agents. However, the extent of gadolinium deposition varies between agents. (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Vikas Gulani, Fernando Calamante, Frank G Shellock, Emanuel Kanal, Scott B Reeder, International Society for Magnetic Resonance in Medicine Tags: Personal View Source Type: research
[Review] Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches
Progressive supranuclear palsy (PSP), previously believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and behavioural syndromes that are associated with a characteristic 4-repeat tau neuropathology. New research criteria that recognise early presentations of PSP and operationalise diagnosis of the full spectrum of clinical phenotypes have been reported. The Movement Disorders Society PSP diagnostic criteria include syndromes with few or mild symptoms that are suggestive of underlying PSP pathology and could provide an opportunity for earlier therapeutic interventions in the future. ...
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Adam L Boxer, Jin-Tai Yu, Lawrence I Golbe, Irene Litvan, Anthony E Lang, G ünter U Höglinger Tags: Review Source Type: research
[Articles] Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study
Psychological factors (ie, emotional distress and maladaptive coping experienced early after injury) in combination with pre-injury mental health problems, education, and age are important predictors for recovery at 6 months following mTBI. These findings provide targets for early interventions to improve outcome in a subgroup of patients at risk of incomplete recovery from mTBI, and warrant validation. (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Joukje van der Naalt, Marieke E Timmerman, Myrthe E de Koning, Harm J van der Horn, Myrthe E Scheenen, Bram Jacobs, Gerard Hageman, Tansel Yilmaz, Gerwin Roks, Jacoba M Spikman Tags: Articles Source Type: research
[In Context] The cerebrovascular health of Thomas Aquinas
On Dec 6, 1273, theologian and philosopher, Thomas Aquinas, had visions and experienced a spiritual transformation that radically affected his subsequent behaviour.1 –3 He claimed that, in comparison with the visions that he interpreted as being sent from God, the essays he had written in the past seemed meaningless and “like straw”.2,3 Around the same date, his health started to decline leaving him in need of bed-rest.1–3 (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Philippe Charlier, Deo Saudamini, Donatella Lippi, Antonio Perciaccante, Otto Appenzeller, Raffaella Bianucci Tags: In Context Source Type: research
[In Context] Tiffany Braley
Tiffany Braley is an Assistant Professor of Neurology, a multiple sclerosis specialist, and a clinical sleep researcher at the University of Michigan (Ann Arbor, MI, USA). Her research focuses on the role of sleep disorders as treatable contributors to fatigue, cognitive function, and other outcomes in patients with multiple sclerosis. She is also interested in the interface between immunology and sleep. (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Tags: In Context Source Type: research
[Correspondence] Atrial fibrillation in high-risk patients with ischaemic stroke – Authors' reply
We agree with Stefan Knecht and colleagues that the rehabilitation setting is ideal for doing prolonged Holter-electrocardiogram monitoring for the detection of atrial fibrillation. We think that this approach should be studied in a randomised trial. (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Rolf Wachter, Klaus Gr öschel, Find-AF Investigators and Coordinators Tags: Correspondence Source Type: research
[Correspondence] Atrial fibrillation in high-risk patients with ischaemic stroke
In their Article, Rolf Wachter and colleagues1 report important evidence for secondary prevention after stroke and show that, after non-large-artery stroke, three 10-day Holter-electrocardiograms (ECGs) increased the detection rate of atrial fibrillation by 9% compared with standard care involving only one 24 h Holter-ECG. The authors point out that long-term Holter-ECGs were easier to integrate into the routine work-up than specialised external loop recorders or implanted devices because they were widely available, familiar to most physicians, and inexpensive. (Source: Lancet Neurology)
Source: Lancet Neurology - June 14, 2017 Category: Neurology Authors: Stefan Knecht, Sebastian Petsch, Bettina Studer Tags: Correspondence Source Type: research
